Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Microbiol Resour Announc ; 13(3): e0102523, 2024 Mar 12.
Article in English | MEDLINE | ID: mdl-38299840

ABSTRACT

We report the complete genome sequence of deformed wing virus and black queen cell virus isolated from Argentinean's honeybees. These sequence data will be valuable for future research on the viral variants present in the country and the development of strategies to control the spread of these viruses in apiaries.

2.
Rev Argent Microbiol ; 56(2): 125-133, 2024.
Article in English | MEDLINE | ID: mdl-38143232

ABSTRACT

Bovine respiratory syncytial virus (BRSV) affects both beef and dairy cattle, reaching morbidity and mortality rates of 60-80% and 20%, respectively. The aim of this study was to obtain a recombinant MVA expressing the BRSV F protein (MVA-F) as a vaccine against BRSV and to evaluate the immune response induced by MVA-F after systemic immunization in homologous and heterologous vaccination (MVA-F alone or combined with a subunit vaccine), and after intranasal immunization of mice. MVA-F administered by intraperitoneal route in a homologous scheme elicited levels of neutralizing antibodies similar to those obtained with inactivated BRSV as well as better levels of IFN-γ secretion. In addition, nasal administration of MVA-F elicited local and systemic immunity with a Th1 profile. This study suggests that MVA-F is a good candidate for further evaluations combining intranasal and intramuscular routes, in order to induce local and systemic immune responses, to improve the vaccine efficacy against BRSV infection.


Subject(s)
Administration, Intranasal , Mice, Inbred BALB C , Respiratory Syncytial Virus, Bovine , Animals , Respiratory Syncytial Virus, Bovine/immunology , Mice , Female , Cattle , Viral Fusion Proteins/immunology , Viral Fusion Proteins/genetics , Viral Fusion Proteins/administration & dosage , Respiratory Syncytial Virus Vaccines/immunology , Respiratory Syncytial Virus Vaccines/administration & dosage , Genetic Vectors , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/veterinary , Vaccinia virus/immunology , Vaccinia virus/genetics , Antibodies, Viral/blood , Immunity, Mucosal , Antibodies, Neutralizing/blood , Antibodies, Neutralizing/immunology , Immunization/methods , Vaccines, Subunit/immunology , Vaccines, Subunit/administration & dosage
3.
Poblac. salud mesoam ; 21(1): 1-14, jul.-dic. 2023.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1575384

ABSTRACT

Resumen Objetivo: determinar la seroprevalencia de anticuerpos contra SARS-CoV-2. Metodología: para ello, entre el 21 de noviembre y el 12 de diciembre del año 2020, se desarrolló un estudio transversal en 1182 muestras de residentes de un municipio bonaerense en la Provincia de Buenos Aires, Argentina. Se midió IgG por ELISA en muestras obtenidas vía digitopunción. Resultados: la prevalencia general fue del 12,2 % (n = 144; IC95 %: 10,3 - 14,0) con un cociente 1:3,8 entre la incidencia acumulada y la observación en nuestro estudio; en mujeres fue del 13,0 % (IC95 %: 10,2 - 15,7) y en hombres, del 10,5 % (IC95 %: 7,6 - 13,3) (p = 0.21). Las prevalencias en grupos etarios fueron las siguientes: 18 a 30 años, del 17,8 % (IC95 %: 12,0 - 23,6); 31 a 60 años, del 12,2 % (IC95 %: 9,3 - 15,1) y 61 años o más, del 9.9 % (IC95 %: 6.9 - 13.9) (p = 0.02). Las prevalencias según los terciles socioeconómicos (por Necesidades Básicas Insatisfechas) fueron para el Tercil I (mejor tercil): 7,7 % (IC95 %: 4,7 - 10,7); el Tercil II: 12.5 % (IC95 %: 8,7 - 16,4); y el Tercil III: 15,2 % (IC95 %: 11,6 - 18,8) (p = 0.002). Conclusiones: también hubo diferencias entre las localidades de dicho municipio y entre variables clínicas autorrefenciadas. Se detectaron 12 muestras positivas para IgM: el 1 % del total y el 8,3 % respecto de los casos IgG-positivos. Los estudios de seroprevalencia resultan útiles y podrían contribuir a modelizaciones matemáticas más ajustadas.


Abstract Objective: determine the prevalence of anti-bodies against SARS-CoV-2. Method: between November twenty-one and December twelve of two thousand and twenty year, a cross-sectional study was carried out in 1182 samples from residents of a Buenos Aires town in the Province of Buenos Aires, Argentina. IgG was measured by ELISA in samples obtained by acupressure. Results: the global prevalence was 12.2 % (n = 144; 95 % CI: 10.3 - 14.0) with a ratio of 1: 3.8, between cumulative incidence and observational values. Prevalence in women and men were 13.0 % (95 % CI: 10.2 - 15.7) and 10.5 % (95 % CI: 7.6 - 13.3), respectively (p = 0.21). By age, the observed values were: 17.8 % (95 % CI: 12.0 - 23.6) in 18 and 30 years old group; 12.2 % (95 % CI: 9.3 - 15.1) in 31 to 60 years old group, 9.9 % (95 % CI: 6.9 - 13.9) in people over 61 years old (p = 0.02). According the socioeconomic tertiles (for Unsatisfied Basic Needs) the prevalence values were 7.7 % (95 % CI: 4.7 - 10.7) for Tertile I (best tertile), 12.5 % (95 % CI: 8.7 - 16.4) for Tertile II, and 15.2 % (95 % CI: 11.6 - 18.8) for Tertile III (p = 0.002). Conclusion: there were also differences between the neighbourhoods and between self-reported clinical variables. Specific IgM antibodies were detected in 12 samples, which represented 1% of the total. Seroprevalence studies provide useful information that can be apllied to fit modeling.

4.
Viruses ; 15(6)2023 06 16.
Article in English | MEDLINE | ID: mdl-37376681

ABSTRACT

The second wave of COVID-19 occurred in South America in early 2021 and was mainly driven by Gamma and Lambda variants. In this study, we aimed to describe the emergence and local genomic diversity of the SARS-CoV-2 Lambda variant in Argentina, from its initial entry into the country until its detection ceased. Molecular surveillance was conducted on 9356 samples from Argentina between October 2020 and April 2022, and sequencing, phylogenetic, and phylogeographic analyses were performed. Our findings revealed that the Lambda variant was first detected in Argentina in January 2021 and steadily increased in frequency until it peaked in April 2021, with continued detection throughout the year. Phylodynamic analyses showed that at least 18 introductions of the Lambda variant into the country occurred, with nine of them having evidence of onward local transmission. The spatial--temporal reconstruction showed that Argentine clades were associated with Lambda sequences from Latin America and suggested an initial diversification in the Metropolitan Area of Buenos Aires before spreading to other regions in Argentina. Genetic analyses of genome sequences allowed us to describe the mutational patterns of the Argentine Lambda sequences and detect the emergence of rare mutations in an immunocompromised patient. Our study highlights the importance of genomic surveillance in identifying the introduction and geographical distribution of the SARS-CoV-2 Lambda variant, as well as in monitoring the emergence of mutations that could be involved in the evolutionary leaps that characterize variants of concern.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Argentina/epidemiology , SARS-CoV-2/genetics , Phylogeny , COVID-19/epidemiology , Mutation
5.
Viruses ; 15(2)2023 01 22.
Article in English | MEDLINE | ID: mdl-36851525

ABSTRACT

The COVID-19 pandemic has lately been driven by Omicron. This work aimed to study the dynamics of SARS-CoV-2 Omicron lineages during the third and fourth waves of COVID-19 in Argentina. Molecular surveillance was performed on 3431 samples from Argentina, between EW44/2021 and EW31/2022. Sequencing, phylogenetic and phylodynamic analyses were performed. A differential dynamic between the Omicron waves was found. The third wave was associated with lineage BA.1, characterized by a high number of cases, very fast displacement of Delta, doubling times of 3.3 days and a low level of lineage diversity and clustering. In contrast, the fourth wave was longer but associated with a lower number of cases, initially caused by BA.2, and later by BA.4/BA.5, with doubling times of about 10 days. Several BA.2 and BA.4/BA.5 sublineages and introductions were detected, although very few clusters with a constrained geographical distribution were observed, suggesting limited transmission chains. The differential dynamic could be due to waning immunity and an increase in population gatherings in the BA.1 wave, and a boosted population (for vaccination or recent prior immunity for BA.1 infection) in the wave caused by BA2/BA.4/BA.5, which may have limited the establishment of the new lineages.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , SARS-CoV-2/genetics , COVID-19/epidemiology , Argentina/epidemiology , Pandemics , Phylogeny
6.
Vet Sci ; 9(5)2022 May 02.
Article in English | MEDLINE | ID: mdl-35622749

ABSTRACT

The honeybee Apis mellifera is highly appreciated worldwide because of its products, but also as it is a pollinator of crops and wild plants. The beehive is vulnerable to infections due to arthropods, fungi, protozoa, bacteria and/or viruses that manage to by-pass the individual and social immune mechanisms of bees. Due to the close proximity of bees in the beehive and their foraging habits, infections easily spread within and between beehives. Moreover, international trade of bees has caused the global spread of infections, several of which result in significant losses for apiculture. Only in a few cases can infections be diagnosed with the naked eye, by direct observation of the pathogen in the case of some arthropods, or by pathogen-associated distinctive traits. Development of molecular methods based on the amplification and analysis of one or more genes or genomic segments has brought significant progress to the study of bee pathogens, allowing for: (i) the precise and sensitive identification of the infectious agent; (ii) the analysis of co-infections; (iii) the description of novel species; (iv) associations between geno- and pheno-types and (v) population structure studies. Sequencing of bee pathogen genomes has allowed for the identification of new molecular targets and the development of specific genotypification strategies.

7.
Front Vet Sci ; 9: 790058, 2022.
Article in English | MEDLINE | ID: mdl-35310416

ABSTRACT

SARS-CoV-2 reverse zoonosis, particularly to domestic animals, and the potential role of infected animals in perpetuating the spread of the virus is an issue of increasing concern. In this case report, we identified the natural infection of two cats by SARS-CoV-2, in Argentina, whose owner had been previously infected by SARS-CoV-2. Viral genetic material was detected in feline oropharyngeal (OP) and rectal (R) swab by RT-qPCR, and sequence analysis revealed that the virus infecting the owner and one cat were genetically similar. The alpha variant (B.1.1.7 lineage) was identified with a unique additional mutation, strongly suggesting human-to-cat route of transmission. This study reinforces the One Health concept and the importance of integrating human, animal, and environmental perspectives to promptly address relevant health issues.

8.
Front Med (Lausanne) ; 8: 755463, 2021.
Article in English | MEDLINE | ID: mdl-34957143

ABSTRACT

SARS-CoV-2 variants with concerning characteristics have emerged since the end of 2020. Surveillance of SARS-CoV-2 variants was performed on a total of 4,851 samples from the capital city and 10 provinces of Argentina, during 51 epidemiological weeks (EWs) that covered the end of the first wave and the ongoing second wave of the COVID-19 pandemic in the country (EW 44/2020 to EW 41/2021). The surveillance strategy was mainly based on Sanger sequencing of a Spike coding region that allows the identification of signature mutations associated with variants. In addition, whole-genome sequences were obtained from 637 samples. The main variants found were Gamma and Lambda, and to a lesser extent, Alpha, Zeta, and Epsilon, and more recently, Delta. Whereas, Gamma dominated in different regions of the country, both Gamma and Lambda prevailed in the most populated area, the metropolitan region of Buenos Aires. The lineages that circulated on the first wave were replaced by emergent variants in a term of a few weeks. At the end of the ongoing second wave, Delta began to be detected, replacing Gamma and Lambda. This scenario is consistent with the Latin American variant landscape, so far characterized by a concurrent increase in Delta circulation and a stabilization in the number of cases. The cost-effective surveillance protocol presented here allowed for a rapid response in a resource-limited setting, added information on the expansion of Lambda in South America, and contributed to the implementation of public health measures to control the disease spread in Argentina.

9.
Acta bioquím. clín. latinoam ; Acta bioquím. clín. latinoam;55(4): 490-500, dic. 2021. graf
Article in Spanish | LILACS, BINACIS | ID: biblio-1393753

ABSTRACT

Resumen La detección de SARS-CoV-2 y su implicancia en el diagnóstico de COVID-19 han sido muy debatidas en la pandemia. El objetivo de este estudio fue evaluar el costo/beneficio de la detección de SARS-CoV-2 en contactos estrechos asintomáticos (CE) mediante el uso de distintas pruebas de diagnóstico molecular. Se estudiaron 51 CE de personas con diagnóstico de SARS-CoV-2 confirmado por RTqPCR, clasificadas por el umbral de ciclos (Ct) (<20, entre 20 y 30 y >30) en hospitales públicos de la provincia de Buenos Aires. Del total de contactos estudiados el 15,7% resultó confirmado para SARS-CoV-2; no hubo contactos positivos de casos con Ct>30. La cantidad de contactos positivos de casos con Ct<20 fue significativamente mayor que la de casos con Ct>20. Las muestras con Ct<20 se asociaron a una carga viral estimada de entre uno a cuatro órdenes de magnitud de diferencia con los rangos de Ct>20. Un 13,7% de contactos positivos fueron casos con Ct<20. De las muestras positivas confirmadas por PCR, correspondientes a la semana epidemiológica 1 de 2021 (SE1), sólo un 19,35% correspondían a muestras con Ct<20 y un 50,7% con Ct entre 20 y 30. Estos datos muestran un incremento de sólo un 3,7% de casos detectados. El esfuerzo por parte del sistema de salud pública para esta estrategia, con bajo poder predictivo, puede tener un efecto negativo para el cumplimiento del aislamiento de los contactos y podría generar una demora en los resultados de los casos sospechosos, sin aportar significativamente en el control de la pandemia.


Abstract The detection of SARS-CoV-2 and its implication in the diagnosis of COVID-19 have been highly debated in the pandemic. The objective of this study was to evaluate the cost/benefit of detecting SARS-CoV-2 in asymptomatic close contacts (CC) using different molecular diagnostic tests. A total of 51 CC of people with a diagnosis of SARS-CoV-2 confirmed by RTqPCR, classified by the cycle threshold (Ct) (<20, between 20 and 30 and >30), were studied in public hospitals in the Province of Buenos Aires. Of the total contacts studied, 15.7% were confirmed for SARS-CoV-2; there were no positive contacts of cases with Ct>30 positive. The number of positive contacts of cases with Ct<20 was significantly higher than that of cases with Ct>20. Samples with Ct<20 were associated with an estimated viral load of one to four orders of magnitude difference with Ct ranges >20. A total of 13.7% of positive close contacts were from cases with Ct<20. When studying positive samples with confirmed diagnosis by PCR, corresponding to 1 epidemiological week of 2021 (EW1), only 19.35% corresponded to samples with Ct<20 and 50.7% with Ct between 20 and 30. From these data it is shown that with the CC test only 3.7% of the cases were detected. The effort by the public health system for this strategy, with low predictive power, may have a negative effect on the fulfillment of the isolation of contacts and could generate a delay in the results of suspected cases, without contributing significantly to controlling the pandemic.


Resumo A detecção do SARS-CoV-2 e seu envolvimento no diagnóstico da COVID-19 têm sido muito discutidos durante a pandemia. O objetivo desse estudo foi avaliar a relação custo/benefício na detecção de SARSCoV- 2 em casos de contatos próximos assintomático (CP), por meio do uso de diferentes testes de diagnóstico molecular. Foram estudados 51 casos de CP de pessoas com diagnóstico de SARS-CoV-2 confirmado pelo RTqPCR, sendo classificados pelo limiar de ciclos (Ct) (<20, entre 20 e 30 e >30), em hospitais públicos da província de Buenos Aires. Do total de contatos estudados, 15,7% foram confirmados para SARS-CoV-2, não houve contatos positivos de casos com Ct>30. O número de contatos positivos de casos com Ct<20, foi significativamente maior que os casos com Ct>20. As amostras com Ct<20 foram associadas a uma carga viral estimada de uma a quatro ordens de magnitude de diferença com os intervalos de Ct>20. Dos casos positivos, 13,7% foram com Ct<20. Das amostras positivas confirmadas por PCR, correspondentes à semana epidemiológica 1 de 2021 (SE1), apenas 19,35% correspondiam a amostras com Ct>20 e 50,7% com Ct entre 20 e 30. Esses dados mostram incremento de apenas 3,7% de casos detectados. O esforço por parte do sistema de saúde pública para essa estratégia, com baixo poder preditivo, pode ter um efeito negativo no cumprimento do isolamento dos contatos e poderia gerar uma demora nos resultados dos casos suspeitos, sem contribuir significativamente para o controle da pandemia.


Subject(s)
Virology , SARS-CoV-2 , Patient Isolation , Salaries and Fringe Benefits , Health Systems , Power, Psychological , Carrier State , Polymerase Chain Reaction , Public Health , Viral Load , Diagnostic Techniques and Procedures , Costs and Cost Analysis , Richter Scale , Molecular Diagnostic Techniques , Diagnosis , Pathology, Molecular , Pandemics , Procrastination , COVID-19 , Hospitals, Public , Persons
10.
J Gen Virol ; 102(3)2021 03.
Article in English | MEDLINE | ID: mdl-33528348

ABSTRACT

Bluetongue (BT) is an insect-borne disease affecting domestic and wild ruminants. Bluetongue virus (BTV) is the causative agent of the BT disease. BT outbreaks have been widely recorded worldwide. However, in the South American subcontinent, accurate information about the disease and molecular epidemiology is still lacking because little effort has been made to cover the region. This study comprises an exhaustive phylogenetic analysis including all BTV sequences available in databases and reports new Argentinean sequences for Seg 8 and Seg 9. Maximum-likelihood phylogenetic analyses were conducted for Seg 2, Seg 3, Seg 6, Seg 7, Seg 8, Seg 9 and Seg 10. Throughout the study, wide circulation and genetic continuity along the American continent were detected. Also, reassortment events are reported, and the historical virus introduction path into and through South America is suggested.


Subject(s)
Bluetongue virus/classification , Bluetongue virus/genetics , Bluetongue/virology , Animals , Argentina/epidemiology , Bluetongue/epidemiology , Bluetongue virus/isolation & purification , Evolution, Molecular , Molecular Epidemiology , Phylogeny , Reassortant Viruses/genetics , South America/epidemiology
11.
Front Vet Sci ; 6: 359, 2019.
Article in English | MEDLINE | ID: mdl-31681812

ABSTRACT

Serological evidence suggests that HoBi-like viruses, an emerging species within the Pestivirus genus of the Flaviviridae family, are in circulation in Argentina. While HoBi-like viruses were first isolated from Brazilian fetal bovine serum (FBS), no survey of Argentine FBS has been conducted. Therefore, 124 local samples of non-irradiated FBS originating from Argentina were surveyed for the presence of pestiviruses using RT-PCR. Amplicons from pestivirus positive samples were genotyped. Four samples were positive for HoBi virus-specific RT-PCR, while the BVDV-positive samples (n = 45) were classified as BVDV-1b (82.2%), BVDV-1a (13.3%), and BVDV-2 (4.5%). Virus isolation and serological profile assessment were performed for the four HoBi-positive FBS lots. These results confirm the circulation of HoBi-like virus in some regions of the Argentinean territory, highlighting the need to review the diagnostic techniques currently used in the clinical cases suspected of BVDV and in contamination control protocols for adventitious agents in cells and biotechnological products.

12.
Rev Argent Microbiol ; 50(3): 275-279, 2018.
Article in English | MEDLINE | ID: mdl-29198455

ABSTRACT

Bovine respiratory syncytial virus (BRSV) is one of the causative agents of respiratory disease in cattle all over the world, leading to important economic losses. The aim of this work was to determine the seroprevalence of BRSV in feedlot cattle of Argentina and the risk factors associated with the disease. Results showed a high individual seroprevalence of 78.64% (95% confidence interval adjusted [CI]=66.55-90.75%) against the virus. Positive association was found between the presence of high BRSV neutralizing antibody titers, and the following risk factors: cattle age, source of animals, presence of clinical respiratory signs and herd size. This work contributes to updating the understanding of its epidemiology in Argentinean feedlots and poses the need for reevaluating vaccination strategies against this virus in order to control infection and its impact on productivity.


Subject(s)
Cattle Diseases , Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus, Bovine , Seroepidemiologic Studies , Animals , Antibodies, Viral , Argentina/epidemiology , Cattle , Cattle Diseases/epidemiology , Cattle Diseases/virology , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/veterinary , Risk Factors
13.
Plant Biotechnol J ; 13(8): 1071-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26250843

ABSTRACT

Vaccination has proved to be an efficient strategy to deal with viral infections in both human and animal species. However, protection of cattle against viral infections is still a major concern in veterinary science. During the last two decades, the development of efficient plant-based expression strategies for recombinant proteins prompted the application of this methodology for veterinary vaccine purposes. The main goals of viral bovine vaccines are to improve the health and welfare of cattle and increase the production of livestock, in a cost-effective manner. This review explores some of the more prominent recent advances in plant-made viral bovine vaccines against foot-and-mouth disease virus (FMDV), bovine rotavirus (BRV), bovine viral diarrhoea virus (BVDV), bluetongue virus (BTV) and bovine papillomavirus (BPV), some of which are considered to be the most important viral causative agents of economic loss in cattle production.


Subject(s)
Cattle Diseases/immunology , Cattle Diseases/virology , Viral Vaccines/immunology , Virus Diseases/veterinary , Animals , Cattle , Plants , Virus Diseases/immunology , Virus Diseases/virology
14.
Virus Res ; 182: 87-94, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24239973

ABSTRACT

Bluetongue virus (BTV) has been detected in many parts of the world but the data available from each continent are substantially different. Some regions are not covered by proper surveillance programs and thus, the real situation concerning the incidence of BTV in those regions is unknown. This is the case of Central America, South America and the Caribbean, where few outdated data about the presence and spread of BTV have been reported. In the present review, we update the BTV situation in those regions by compiling the serologic data available and analyzing the genetic information reported by the different research groups which are studying the disease in the region.


Subject(s)
Bluetongue virus/classification , Bluetongue virus/isolation & purification , Bluetongue/epidemiology , Animals , Bluetongue virus/genetics , Caribbean Region/epidemiology , Central America/epidemiology , Genetic Variation , Seroepidemiologic Studies , South America/epidemiology
15.
Curr Pharm Des ; 19(31): 5612-21, 2013.
Article in English | MEDLINE | ID: mdl-23394557

ABSTRACT

Molecular farming is a technology that is very well suited to being applied in developing countries, given the reasonably high level of expertise in recombinant plant development in many centers. In addition, there is an urgent need for products such as inexpensive vaccines and therapeutics for livestock and for some human diseases - and especially those that do not occur or are rare in developed regions. South Africa and Argentina have been at the fore in this area among developing nations, as researchers have been able to use plants to produce experimental therapeutics such as nanoantibodies against rotavirus and vaccines against a wide variety of diseases, including Rabbit haemorrhagic disease virus, Foot and mouth disease virus, Bovine viral diarrhoea virus, bovine rotaviruses, Newcastle disease virus, rabbit and human papillomaviruses, Bluetongue virus, and Beak and feather disease virus of psittacines. A combination of fortuitous scientific expertise in both places, coupled with association with veterinary and human disease research centers, has enabled the growth of research groups that have managed to compete successfully with others in Europe and the USA and elsewhere, to advance this field. This review will cover relevant work from both South Africa and Argentina, as well as a discussion about the perspectives in this field for developing nations.


Subject(s)
Molecular Farming/methods , Plants, Genetically Modified , Recombinant Proteins/biosynthesis , Animal Diseases/prevention & control , Animals , Argentina , Cattle , Developing Countries , Humans , Rabbits , South Africa , Vaccines/biosynthesis , Vaccines/immunology , Veterinary Drugs/administration & dosage , Veterinary Drugs/immunology
16.
Vet Immunol Immunopathol ; 151(3-4): 315-24, 2013 Feb 15.
Article in English | MEDLINE | ID: mdl-23291101

ABSTRACT

Bovine viral diarrhea virus (BVDV) is considered an important cause of economic loss within bovine herds worldwide. In Argentina, only the use of inactivated vaccines is allowed, however, the efficacy of inactivated BVDV vaccines is variable due to its low immunogenicity. The use of recombinant subunit vaccines has been proposed as an alternative to overcome this difficulty. Different studies on protection against BVDV infection have focused the E2 protein, supporting its putative use in subunit vaccines. Utilization of transgenic plants expressing recombinant antigens for the formulation of experimental vaccines represents an innovative and cost effective alternative to the classical fermentation systems. The aim of this work was to develop transgenic alfalfa plants (Medicago sativa, L.) expressing a truncated version of the structural protein E2 from BVDV fused to a molecule named APCH, that target to antigen presenting cells (APCH-tE2). The concentration of recombinant APCH-tE2 in alfalfa leaves was 1 µg/g at fresh weight and its expression remained stable after vegetative propagation. A methodology based an aqueous two phases system was standardized for concentration and partial purification of APCH-tE2 from alfalfa. Guinea pigs parentally immunized with leaf extracts developed high titers of neutralizing antibodies. In bovine, the APCH-tE2 subunit vaccine was able to induce BVDV-specific neutralizing antibodies. After challenge, bovines inoculated with 3 µg of APCH-tE2 produced in alfalfa transgenic plants showed complete virological protection.


Subject(s)
Bovine Virus Diarrhea-Mucosal Disease/prevention & control , Diarrhea Virus 1, Bovine Viral/immunology , Medicago sativa/genetics , Medicago sativa/immunology , Viral Vaccines/pharmacology , Animals , Antibodies, Neutralizing/biosynthesis , Antibodies, Viral/biosynthesis , Bovine Virus Diarrhea-Mucosal Disease/immunology , Bovine Virus Diarrhea-Mucosal Disease/virology , Cattle , Diarrhea Virus 1, Bovine Viral/genetics , Female , Guinea Pigs , Male , Plants, Genetically Modified , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Treatment Outcome , Vaccination/veterinary , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/pharmacology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Vaccines/genetics , Viral Vaccines/immunology
17.
Vet Microbiol ; 151(3-4): 255-63, 2011 Aug 05.
Article in English | MEDLINE | ID: mdl-21550733

ABSTRACT

We describe the progression of Bovine Leukemia Virus (BLV) infection from birth until the first lactation in 61 animals from a typical large dairy herd of Argentina, with more than 85% of prevalence. The purpose was to identify potential points to effectively break the BLV cycle of transmission in our dairy productive system. We detected early infection in 11.47% of newborn calves by nested PCR. From birth to 12 months, no evidence of new infections was observed. After 12 months of age, the detection of new reactors increased slowly with time, from 15.09% at 15 months to 24% at 27 months. After that, the number of reactors increased rapidly up to 40% and 60.76% at 30 and 36 months, respectively. This last 9-month period coincided with parturition and the entry into the milking herd. Real-time PCR showed that more than 75% of adult animals had low peripheral-blood proviral load. Complementary, all infected animals showed low levels of provirus in milk and colostrum. The most important finding was that even when management procedures to prevent BLV iatrogenic transmission were followed, no significant change was observed in the prevalence after three years, strongly suggesting that other way/s of transmission play a key role under natural conditions. This study showed an interesting baseline to draw an alternative approach based on selective segregation according to the peripheral-blood proviral load as a potential indicator of risk transmission, and as an alternative to classical control measures.


Subject(s)
Cattle/virology , Enzootic Bovine Leukosis/pathology , Leukemia Virus, Bovine/pathogenicity , Animals , Animals, Newborn/virology , Antibodies, Viral/blood , Argentina/epidemiology , DNA, Viral/blood , Disease Progression , Enzootic Bovine Leukosis/epidemiology , Enzootic Bovine Leukosis/transmission , Enzootic Bovine Leukosis/virology , Female , Lactation , Leukemia Virus, Bovine/isolation & purification , Milk/virology , Polymerase Chain Reaction/veterinary , Pregnancy , Prevalence , Proviruses/isolation & purification , Proviruses/pathogenicity , Vaccination/veterinary , Viral Load
18.
Vet Immunol Immunopathol ; 137(1-2): 155-60, 2010 Sep 15.
Article in English | MEDLINE | ID: mdl-20546933

ABSTRACT

Group A bovine rotavirus (BRV) is the major cause of acute viral gastroenteritis in neonatal calves worldwide. Due to the early susceptibility to the infection prevention strategies are based on the improvement of passive immunity levels through cow vaccination in the last third of gestation. The major capsid antigen (VP6) of BRV is the most immunogenic viral protein and it is highly conserved among group A BRV. In this work, VP6 protein from BRV C-486 strain (P[1]G6) was expressed in insect cells using the baculovirus expression vector system. Recombinant VP6 was used to immunize cows and vaccine's efficacy was assessed in a colostrum-deprived calf model of BRV infection and disease. Immune colostrum pool was generated using first and second milking of the immunized cows. Calves receiving one dose of immune colostrum within the first 6h of life, or colostrum-deprived calves were orally inoculated with virulent BRV at 2 days of age. The animals were monitored for diarrhea, virus shedding and isotype-specific antibodies responses to BRV in both feces and serum. Calves receiving VP6-immune colostrum showed a reduction of both diarrhea and virus shedding (in terms of viral titer and excretion period) in comparison with the colostrum-deprived calves.


Subject(s)
Antigens, Viral/immunology , Capsid Proteins/immunology , Cattle Diseases/prevention & control , Rotavirus Infections/veterinary , Rotavirus Vaccines/immunology , Animals , Animals, Newborn , Antibodies, Viral/blood , Cattle , Colostrum/immunology , Diarrhea/prevention & control , Diarrhea/veterinary , Feces/virology , Female , Immunization , Rotavirus Infections/prevention & control , Virus Shedding
19.
Planta ; 231(2): 387-95, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20041332

ABSTRACT

Chloroplast transformation has an extraordinary potential for antigen production in plants because of the capacity to accumulate high levels of recombinant proteins and increased biosafety due to maternal plastid inheritance in most crops. In this article, we evaluate tobacco chloroplasts transformation for the production of a highly immunogenic epitope containing amino acid residues 135-160 of the structural protein VP1 of the foot and mouth disease virus (FMDV). To increase the accumulation levels, the peptide was expressed as a fusion protein with the beta-glucuronidase reporter gene (uidA). The recombinant protein represented the 51% of the total soluble proteins in mature leaves, a level higher than those of the Rubisco large subunit, the most abundant protein in the leaf of a wild-type plant. Despite this high accumulation of heterologous protein, the transplastomic plants and wild-type tobacco were phenotypically indistinguishable. The FMDV epitope expressed in transplastomic plants was immunogenic in mice. These results show that transplastomic tobacco express efficiently the recombinant protein, and we conclude that this technology allows the production of large quantities of immunogenic proteins.


Subject(s)
Chloroplasts/genetics , Chloroplasts/virology , Epitopes/immunology , Foot-and-Mouth Disease Virus/immunology , Nicotiana/genetics , Nicotiana/virology , Transformation, Genetic , Animals , Capsid Proteins/chemistry , Foot-and-Mouth Disease/virology , Genetic Vectors/genetics , Glucuronidase/metabolism , Mice , Phenotype , Plant Proteins/metabolism , Plants, Genetically Modified
20.
Vaccine ; 27(1): 136-45, 2009 Jan 01.
Article in English | MEDLINE | ID: mdl-18973781

ABSTRACT

Brucella spp. lumazine synthase (BLS) is a highly immunogenic decameric protein. It has been previously evaluated as a carrier to increase the immunogenicity of peptides fused to its N-termini. VP8 is a sialic acid binding domain of rotavirus external capsid protein VP4, which is involved in virus adhesion to host cells. In this work, the C486 bovine rotavirus (BRV) VP8 core protein (VP8d) was fused to the structure of BLS with the aim to produce an enhancement of the immune response against BRV VP8 and to evaluate the possible use of this antigen for vaccine development. The feasibility of using BLS as an antigen delivery system of polypeptides larger in size than those previously tested was also evaluated. Groups of female mice were immunized with BLS-VP8d fusion protein, VP8d or an equimolar mixture of purified VP8d and BLS (BLS+VP8d). Dams immunized with BLS-VP8 induced 97.5-100% protection against homologous challenge with C486 BRV; while pups born to dams immunized either with VP8d or BLS+VP8d presented a significant lower level of protection. The neutralizing antibody pattern was also significantly different among these experimental groups, and in concordance with challenge experiment. Overall, these results demonstrate that the BLS-VP8d chimeric protein is properly folded and stable, and that the BLS scaffold is a potent antigen delivery system that enhances the antibody response against BRV and elicits complete homotypic passive protection in a suckling mouse model.


Subject(s)
Brucella/enzymology , Drug Delivery Systems , Rotavirus Infections/prevention & control , Rotavirus Vaccines/immunology , Rotavirus/chemistry , Vaccines, Synthetic/immunology , Animals , Animals, Newborn , Animals, Suckling/immunology , Antibodies, Viral/blood , Brucella/immunology , Cattle , Cells, Cultured , Female , Mice , Mice, Inbred BALB C , Recombinant Fusion Proteins/immunology , Rotavirus/immunology , Rotavirus Vaccines/administration & dosage , Th1 Cells/immunology , Vaccines, Synthetic/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL